ZJK-807

ZJK-807 is a highly effective and selective PROTAC degrader targeting KRASG12D (DC50 = 79.5 nM in AsPC-1 cells) . ZJK-807 shows minimal impact on wild-type KRAS or other mutants (G12C/S/V, G13D), inducing mutant-specific cytotoxicity. ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis. ZJK-807 can be used for the study of KRAS-driven pancreatic cancer. Yellow: KRASG12D ligand (HY-W087383) ; Green: E3 ligase CRBN ligand (HY-178507) ; Black: Linker (HY-178506) [1].

Product Specifications

UNSPSC

12352005

Target

P38 MAPK; PROTACs; Ras; TNF Receptor

Related Pathways

Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; PROTAC

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC(N4CC5(CCC(N(C6CN(C7=NC(N8C[C@@](N9)([H])CC[C@@]9([H])C8)=C(C=NC(C%10=C%11C(C#C)=C(F)C=CC%11=CC(O)=C%10)=C%12F)C%12=N7)C6)C)CC5)C4)=C3)=O

Molecular Formula

C50H48F2N10O5

Molecular Weight

906.98

References & Citations

[1]Liu Z, et al. ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer. J Med Chem. 2025 Oct 9;68 (19) :20103-20129.